Herein, we reported a case of DLBCL/HGBL-MYC/BCL2 transformed from FL during the treatment with BR (bendamustine and rituximab) regimen, was primary refractory to Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone), and ultimately responded to the CD20×CD3 bispecific antibody glofitamab with a long-term partial response. Here, BCL2 is linked to diffuse large B-cell lymphoma.